Sunitinib and luteolin inhibit human renal carcinoma cell invasion via down-regulation of MMPs
碩士 === 中山醫學大學 === 生化暨生物科技研究所 === 100 === Renal cell carcinoma (RCC) is a heterogeneous disease with dismal outcome. Sunitinib is an inhibitor of multiple tyrosine kinase receptors approved for the oral treatment of metastatic RCC. Luteolin, a natural flavonoid wildly existing in plants including fru...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2012
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/3z885e |